Q-omics provides the consensus-scored MT-TI profile across patient tissues and cancer cell-line models. MT-TI expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MT-TI is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MT-TI RNA expression shows 6,152 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, BRCA, and LAML as cancer lineages where MT-TI shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-TI — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-TI survival associations across molecular data types. MT-TI RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-TI RNA expression–survival associations across cancer types. High MT-TI expression shows unfavorable associations in KIRC, UCS, UVM and UCEC, but favorable associations in CESC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MT-TI RNA expression.
This table summarizes MT-TI tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MT-TI. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-TI shows lower tumor expression in BRCA, KIRC and COAD and higher tumor expression in LIHC. The BRCA box plot shows higher MT-TI RNA expression in normal versus tumor tissue (log2 FC = −0.199, t-test p = .023).
This table shows molecular features associated with MT-TI in patient tissues and cancer cell lines. In patient samples, MT-TI shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
